DAYBUE STIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DAYBUE STIX (DAYBUE STIX).
Gamma-aminobutyric acid (GABA) aminotransferase inhibitor; increases brain GABA levels.
| Metabolism | Not significantly metabolized; excreted primarily unchanged in urine. |
| Excretion | Renal: ~70% unchanged; fecal: ~20%; biliary: <5% |
| Half-life | Terminal elimination half-life: 11-14 hours; requires twice-daily dosing for sustained trough concentrations |
| Protein binding | ~30% bound to albumin and α1-acid glycoprotein |
| Volume of Distribution | 0.45-0.6 L/kg; indicates distribution into total body water |
| Bioavailability | Oral: ~55% (range 45-65%) due to first-pass metabolism |
| Onset of Action | Oral: 1-2 hours for measurable CSF concentration; clinical effect onset 2-4 weeks |
| Duration of Action | 12 hours with twice-daily dosing; steady state achieved in 3-5 days |
Administer orally as 15 mg/day for 1 week; increase to 30 mg/day for 1 week; then to 45 mg/day for 1 week; final maintenance dose is 60 mg/day.
| Dosage form | FOR SOLUTION |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, use is not recommended; if used, reduce dose by 50%. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use is not recommended. |
| Pediatric use | Approved for children aged 7 years and older; dosing is weight-based: <20 kg: start 10 mg/day, increase weekly by 10 mg to max 25 mg/day; 20–35 kg: start 15 mg/day, increase weekly by 15 mg to max 35 mg/day; ≥35 kg: start 20 mg/day, increase weekly by 20 mg to max 50 mg/day. |
| Geriatric use | No specific dose adjustment; monitor renal function and consider reduced starting dose due to age-related decline in renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DAYBUE STIX (DAYBUE STIX).
| Breastfeeding | No human data on excretion in breast milk; M/P ratio unknown. Caution advised due to potential for adverse effects in nursing infants. |
| Teratogenic Risk | No human data available; in animal studies, no structural abnormalities observed at clinically relevant doses. Potential risk of fetal harm cannot be excluded. Use only if benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
Permanent vision loss, including concentric visual field constriction, occurs with high frequency; risk increases with cumulative dose and duration.
| Serious Effects |
Hypersensitivity to vigabatrin; pregnancy (weigh risk vs benefit).
| Precautions | Vision loss (regular ophthalmologic monitoring required); sedation/somnolence; neurotoxicity (MRI abnormalities including T2 hyperintensities); withdrawal seizures; suicidal ideation; anemia; edema; weight gain. |
Loading safety data…
| Monitor maternal weight gain, blood pressure, and fetal growth via ultrasound during pregnancy. Assess for signs of fetal distress if maternal seizures occur. |
| Fertility Effects | Limited human data; no reported effects on fertility in animal studies. Potential for hormonal disturbances affecting ovulation in females. |